<?xml-stylesheet type="text/xsl" href="https://community.appian.com/cfs-file/__key/system/syndication/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><title>Drug Benefit Risk Analysis for BRAT Framework</title><link>/b/appmarket/posts/drug-benefit-risk-analysis-for-brat-framework</link><description>Overview 
 Pharmaceutical product benefit-risk assessments play a critical role in bringing new treatments to market, providing information for decisions regarding drug development, licensing and reimbursement, and others. In 2005, the Pharmaceutical</description><dc:language>en-US</dc:language><generator>Telligent Community 12</generator></channel></rss>